10-K: Akebia Therapeutics Reports 2025 Revenue Growth Driven by Vafseo Launch Amidst Auryxia Generic Entry

Akebia Therapeutics saw significant revenue growth in 2025, primarily from the U.S. launch of Vafseo, while navigating generic competition for Auryxia and advancing its rare kidney disease pipeline.

Summary

• Net loss for the year ended December 31, 2025, was $5.3 million, a substantial improvement from $69.4 million in 2024.
• Total revenues increased by 47% to $236.2 million in 2025 from $160.2 million in 2024.
• Net product revenue increased by 49% to $227.3 million in 2025, primarily driven by Vafseo's U.S. market entry in January 2025, which generated $45.8 million.
• Auryxia net product revenue increased to $181.5 million in 2025 from $152.2 million in 2024, despite losing exclusivity in March 2025.
• An authorized generic version of Auryxia has been sold by a distributor since March 20, 2025, and Teva Pharmaceuticals received tentative approval for its generic Auryxia ANDA on January 22, 2026, with additional generic competition expected in 2026.
• Research and Development (R&D) expenses increased by 66% to $62.4 million in 2025, including $12.8 million of acquired in-process R&D costs for AKB-097.
• Selling, General and Administrative (SG&A) expenses increased slightly by 1% to $107.5 million in 2025, due to Vafseo U.S. launch marketing and increased headcount.
• The company initiated a Phase 2 clinical trial for praliciguat in focal segmental glomerulosclerosis (FSGS) in December 2025.
• A Phase 2 basket study for AKB-097 (IgA Nephropathy, C3 Glomerulopathy, Lupus Nephritis) is expected to initiate in the second half of 2026.
• A Phase 1 study for AKB-9090 (cardiac surgery-related acute kidney injury) is expected to initiate in the first half of 2026.
• The company does not plan to pursue a broad label for Vafseo for non-dialysis dependent CKD patients due to FDA feedback requiring a significantly larger and more costly VALOR trial.
• Cash and cash equivalents were $184.8 million as of December 31, 2025.
• The company believes existing cash and expected revenues are sufficient to fund operations for at least two years.
• A new lease agreement for office and lab space in Waltham, Massachusetts, was entered into on January 27, 2026, with relocation planned for September 2026.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing with cautious optimism. While Vafseo's U.S. launch and revenue growth are positive, the significant challenges with Auryxia's loss of exclusivity and the discontinuation of Vafseo's broad non-dialysis label expansion temper the overall sentiment. The pipeline advancements are promising but early-stage, and the company continues to face substantial financial and competitive risks.

Positives

• Net loss significantly reduced to $5.3 million in 2025 from $69.4 million in 2024, indicating improved financial performance.
• Total revenues increased by 47% year-over-year, reaching $236.2 million, demonstrating strong top-line growth.
• Vafseo's successful U.S. market entry in January 2025 generated $45.8 million in net product revenue in its first year.
• Commercial supply agreements for Vafseo are in place with dialysis organizations caring for nearly 100% of U.S. dialysis patients, providing broad access.
• Approximately 290,000 dialysis patients in the U.S. currently have prescribing access to Vafseo through operationalized protocols.
• A post-hoc win-odds analysis of Vafseo's INNO2VATE trials demonstrated favorable and statistically significant effects on death and hospitalization relative to the ESA darbepoetin alfa.
• Advancement of the mid-stage rare kidney disease pipeline with the initiation of a Phase 2 clinical trial for praliciguat in FSGS in December 2025.
• Acquisition of AKB-097, a potential next-generation complement inhibitor with applicability across a wide range of complement-mediated rare kidney diseases.
• Expected initiation of a Phase 1 study for AKB-9090 in cardiac surgery-related acute kidney injury (CS-AKI) in the first half of 2026, expanding the early-stage pipeline.
• Strong cash and cash equivalents position of $184.8 million as of December 31, 2025.
• Remediation of the previously identified material weakness in internal control over financial reporting as of December 31, 2025.

Negatives

• Auryxia lost exclusivity in March 2025, and additional generic competition is expected in 2026, which will adversely impact future revenue from the product.
• Teva Pharmaceuticals Ltd. received tentative approval for its Abbreviated New Drug Application (ANDA) for Auryxia on January 22, 2026, signaling imminent generic market entry.
• Vafseo's U.S. approval is limited to the treatment of anemia due to CKD in adult patients on dialysis for at least three months, a narrower indication than initially pursued.
• The company discontinued plans to pursue a broad label for Vafseo for non-dialysis dependent CKD patients due to FDA feedback requiring a significantly larger and more costly VALOR trial.
• Caution remains regarding a path forward for Vafseo in smaller subpopulations of non-dialysis dependent CKD patients.
• Higher than expected patient discontinuations for Vafseo treatment were observed in 2025, potentially impacting market acceptance.
• Slower than expected patient enrollment and retention challenges in the post-approval pediatric study for Auryxia's hyperphosphatemia indication led to a halt in enrollment and a requested meeting with the FDA.
• Increased R&D expenses by 66% to $62.4 million and SG&A expenses by 1% to $107.5 million in 2025.
• Non-cash interest expense related to the settlement royalty liability increased to $18.4 million in 2025 from $9.3 million in 2024.
• The company has an accumulated deficit of $1.7 billion as of December 31, 2025, reflecting significant historical losses.
• Reliance on single-source suppliers for Auryxia drug substance and drug product, and an exclusive third-party logistics provider for distribution, poses supply chain risks.
• Potential for reduced reimbursement for Vafseo after the Transitional Drug Add-on Payment Adjustment (TDAPA) period expires, without new legislative protection.
• Ongoing litigation by Ardelyx, Inc. challenging CMS's plan to include oral-only phosphate lowering therapies in the ESRD PPS could adversely impact Auryxia revenue if successful.

Risks

• Incurring significant losses and inability to achieve or maintain profitability, requiring substantial additional financing.
• Raising additional capital may cause dilution to existing stockholders, restrict operations, or require relinquishing rights to products on unfavorable terms.
• Failure to successfully identify, acquire, in-license, discover, develop, and commercialize additional products or product candidates.
• Strategic transactions may harm operating results, dilute stockholder ownership, increase debt, or cause significant expense.
• Obligations, requirements, and restrictions in connection with the BlackRock Credit Agreement could adversely affect financial condition and restrict operations.
• Violation of covenants in the Royalty Interest Acquisition Agreement with HealthCare Royalty Partners IV, L.P. could materially adversely affect financial condition.
• Substantial dependence on the commercial success of Auryxia and Vafseo; inability to continue successful commercialization would materially harm results of operations and financial condition.
• Inability to maintain sales and marketing capabilities or enter into/maintain agreements with third parties for commercialization.
• Failure to obtain or maintain adequate coverage, pricing, and reimbursement for Auryxia, Vafseo, or any other future approved products.
• Substantial competition from other pharmaceutical and biotechnology companies, potentially leading to others commercializing products more successfully.
• Risks associated with international operations, including political, regulatory, compliance, economic developments, and foreign currency fluctuations.
• Clinical drug development involves a lengthy and expensive process with an uncertain outcome, leading to additional costs and potential delays or inability to complete development.
• Auryxia, Vafseo, or any other product/candidate may cause undesirable side effects or have other properties that delay/prevent marketing approval or limit commercial potential (e.g., Vafseo's MACE and liver injury risks).
• Inability to obtain marketing approval for any potential label expansion for Vafseo or any current/future product candidate, or significant delays in doing so.
• Inability to obtain orphan drug exclusivity for praliciguat or future product candidates, or such exclusivity not preventing the FDA or EMA from approving competing products.
• Extensive post-marketing regulatory requirements, including post-approval pediatric studies for Auryxia and Vafseo, and potential for post-marketing restrictions or market withdrawal.
• Complex regulatory schemes requiring significant resources; failure to comply could subject the company to government scrutiny, fines, and reputational harm.
• Significant liability if promoting off-label use, improper direct-to-consumer advertising, or violations of the federal Anti-Kickback Statute.
• Disruptions at the FDA and other government agencies from funding cuts, personnel losses, regulatory reform, or government shutdowns could hinder timely guidance and approval.
• Legislative and regulatory healthcare reform may increase the difficulty and cost of obtaining marketing approval and affect prices.
• Dependence on collaborations with third parties for development and commercialization; if unsuccessful or terminated, market potential could be harmed.
• Reliance on third parties to conduct clinical trials and preclinical studies; failure to carry out duties, comply with regulations, or meet deadlines could substantially harm business.
• Risk of the licensor of certain intellectual property relating to Auryxia (Panion) terminating, modifying, or threatening to terminate existing contracts.
• Manufacturing biologics (e.g., AKB-097) is complex, and manufacturing problems could result in development delays.
• Changes in the geopolitical environment, including U.S. and international trade policies (e.g., with China, Europe, Canada), may adversely impact business and operating results.
• Inability to adequately protect intellectual property, allowing third parties to use it and adversely affecting market competition.
• Inability to protect intellectual property rights throughout the world.
• Limited intellectual property and related non-patent exclusivity for current and future products could adversely affect market competition and product value.
• Market entry of one or more generic competitors or third-party challenges to intellectual property rights will likely limit Auryxia and Vafseo sales.
• Litigation and administrative proceedings, including intellectual property infringement claims, may be costly, time-consuming, and delay/harm development efforts.
• Stock price volatility, which could result in substantial losses for stockholders and lawsuits against the company and its officers/directors.
• Failure to comply with Nasdaq's continued listing requirements could lead to delisting and negatively impact stock price and capital access.
• Issuance of additional shares of common stock or sale by significant stockholders will dilute ownership and may cause stock price decline.
• Executive officers, directors, and principal stockholders maintain the ability to significantly influence all matters submitted to stockholders for approval.
• Provisions in organizational documents and Delaware law may have anti-takeover effects.
• No anticipated cash dividends; capital appreciation, if any, will be stockholders' sole source of gain.
• Potential future impairment of long-lived assets (goodwill, property and equipment, right-of-use assets) could significantly impact results of operations and financial condition.
• Product liability lawsuits could result in substantial liabilities and require limiting commercialization or affecting product candidate development.
• Increased costs from operating as a public company and substantial management time devoted to compliance initiatives and corporate governance practices.
• Ability to use net operating losses to offset future taxable income may be subject to certain limitations under Section 382 of the Internal Revenue Code.
• Charter designates the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain stockholder actions, potentially limiting stockholders' ability to choose a favorable judicial forum.
• Security breaches and unauthorized use of information technology systems and information could damage clinical trials, impact regulatory filings, compromise intellectual property, and subject the company to regulatory actions.
• Employees, consultants, or independent contractors may engage in misconduct or other improper activities, including non-compliance with regulatory standards and insider trading.

Future Outlook

The company expects to incur significant R&D expenditures for its ongoing pipeline development (praliciguat, AKB-097, AKB-9090) and continued commercialization of Vafseo and Auryxia. It believes its existing cash resources and expected revenues are sufficient to fund its current operating plan for at least two years. However, the company remains cautious about a path forward for Vafseo in non-dialysis dependent CKD patients following FDA feedback. It anticipates an increase in the cost of product and other revenue for Vafseo once the initial reduced-cost inventory is depleted. The company also expects additional generic competition for Auryxia in 2026, which will adversely impact future revenue.

Management Comments

• "We have built a business focused on developing and commercializing innovative therapeutics that we believe serve as a foundation for future growth, including by contributing net product revenue to support the development and advancement of our robust pipeline of mid-stage programs targeting rare kidney diseases and early-stage programs targeting kidney disease and non-kidney focused indications."
• "We have established the Company as a leader in the kidney community and believe our cross-organizational expertise in kidney disease positions us for success."
• "We believe there is a significant opportunity for Vafseo to become standard of care for the treatment of anemia due to CKD for adult patients on dialysis."
• "We believe our revenue growth for Auryxia has been negatively impacted since 2021 primarily as the CKD patient populations we serve experienced both high hospitalization and mortality rates due to COVID-19 and other infectious diseases, and the availability and uses of vaccines, treatments and therapies has increased."
• "We believe these factors, among others, have contributed to the continued reduction in the phosphate binder market, which has not experienced growth since early 2020."
• "We believe our existing cash resources and the cash we expect to generate from product, royalty, supply and license revenues are sufficient to fund our current operating plan for at least two years, including to commercialize Vafseo and Auryxia and advance our existing programs."

Industry Context

StockSavvy.ai notes that Akebia Therapeutics operates in the highly competitive biopharmaceutical industry, particularly within kidney disease and rare kidney disease segments. The company's strategy to leverage its HIF biology expertise for pipeline expansion aligns with broader industry trends of pursuing novel mechanisms of action and addressing unmet medical needs in specialized areas. The entry of generic competition for Auryxia reflects the typical lifecycle of branded pharmaceuticals, while the challenges in Vafseo's label expansion for non-dialysis patients highlight the stringent regulatory environment and the high bar for demonstrating broad benefit-risk profiles. The ongoing legal challenges to drug pricing and reimbursement policies, such as the Inflation Reduction Act and the Ardelyx lawsuit against CMS, indicate a persistent focus on cost containment and access within the U.S. healthcare system, which could impact all players in the renal therapeutic market.

Comparison to Industry Standards

• Vafseo is the only oral HIF-based treatment available in the U.S. for anemia due to CKD in adult dialysis patients, offering a differentiated mechanism compared to injectable ESAs (e.g., Amgen's Epogen/Aranesp, J&J's Procrit/Eprex, CSL Vifor's Mircera).
• The post-hoc win-odds analysis of Vafseo's INNO2VATE trials demonstrated favorable and statistically significant effects on death and hospitalization compared to the ESA darbepoetin alfa, suggesting a competitive safety/efficacy profile in this specific analysis.
• In the hyperphosphatemia market, Auryxia competes with established phosphate binders like Sanofi's Renagel/Renvela, Fresenius's PhosLo/Phoslyra/Velphoro, Shire's Fosrenol, and over-the-counter calcium carbonate products, many of which are now available in generic forms. Ardelyx's XPHOZAH (tenapanor) also represents a different mechanism (phosphate absorption inhibitor) in this market.
• For IDA, Auryxia competes with various oral iron supplements (ferrous sulfate, gluconate, fumerate) and IV iron formulations (e.g., Feraheme, Venofer, Injectafer, Triferic), as well as Shield Therapeutics' Accrufer (ferric maltol).
• In FSGS, praliciguat is in Phase 2 development, competing with other investigational treatments like Travere Therapeutics' FILSPARI (under FDA review), Dimerix's DMX-200 (Phase 3), and candidates from Apellis, Boehringer Ingelheim, Sanofi, Vera, and Vertex. Currently, there are no FDA-approved drugs specifically indicated for FSGS.
• For IgAN, LN, and C3G, AKB-097 will enter a competitive landscape with approved complement inhibitors like Novartis's FABHALTA, Apellis's EMPAVELI, GSK's BENLYSTA, Aurinia's LUPKYNIS, and Genentech/Biogen's GAZYVA, as well as other pipeline candidates.

Management Changes

Corporate Governance

Legal Proceedings

• Opposition filed by Dr. Reddy's Laboratories Limited in September 2018 against Indian Patent No. 287720 (vadadustat composition of matter); oral hearing held on December 19, 2025, based on amended claims.
• Opposition filed by Sandoz AG on November 6, 2024, against European Patent No. 3007695 (vadadustat once daily dosing regimen); Sandoz withdrew opposition on December 8, 2025, and the EPO discontinued proceedings on January 15, 2026.
• Ardelyx, Inc. filed a complaint in July 2024 against HHS, CMS, and other parties, challenging CMS's plan to include oral-only phosphate lowering therapies in the ESRD PPS; district court denied preliminary injunction and granted motion to dismiss in November 2024; Ardelyx filed notice of appeal on December 26, 2024; oral argument held on September 25, 2025; U.S. Court of Appeals for the Third Circuit rejected AstraZeneca's challenge to Medicare price negotiation program on May 8, 2025.
• The U.S. Supreme Court dismissed the most recent judicial challenge to the ACA in June 2021, but litigation and legislation over the ACA are likely to continue.
• The U.S. District Court for the Northern District of Texas invalidated the FDA approval of mifepristone in April 2023; the Supreme Court reversed that decision in June 2024; an amended complaint was filed by Attorneys General of Missouri, Idaho, and Kansas on October 11, 2024; the district court declined to dismiss and transferred the case to the Eastern District of Missouri on September 30, 2025.
• The company's U.S. federal income tax return for the year ended December 31, 2023, is under examination by the Internal Revenue Service.

Related Party Transactions

• The company has a Royalty Interest Acquisition Agreement with HealthCare Royalty Partners IV, L.P. (HCR), an affiliate of Kreos Capital VII (UK) Limited, which is the lender for the BlackRock Credit Agreement. This agreement involves the sale of rights to Vafseo royalties and sales milestones in Japan and certain other Asian countries.
• The company has a Working Capital Fund liability with CSL Vifor, which also holds 7,571,429 shares of the company's common stock.
• The company has a warrant agreement with Kreos Capital VII Aggregator SCSp, an affiliate of Kreos, for warrants to purchase common stock.

Stakeholder Impact

• Shareholders: Potential for dilution from future capital raises, stock price volatility, and influence of principal stockholders. Positive revenue growth and pipeline advancement could increase shareholder value, but generic competition and regulatory setbacks pose risks.
• Employees: Retention and recruitment challenges in a competitive industry. Compensation programs, stock incentive plans, and benefits are designed to attract and retain talent. The planned relocation to Waltham may impact employees.
• Customers (Dialysis Organizations, Wholesalers, Specialty Pharmacies): Impacted by changes in distribution models, formulary decisions, and reimbursement policies for Auryxia and Vafseo. Generic competition for Auryxia will affect product availability and pricing.
• Patients (CKD, Anemia, Rare Kidney Diseases): Access to Vafseo for dialysis patients is expanding. Development of praliciguat and AKB-097 aims to address unmet needs in rare kidney diseases. Delays in pediatric studies for Auryxia affect a vulnerable patient population.
• Suppliers/Contract Manufacturers: Continued reliance on third-party CMOs and distributors, with risks of supply chain disruptions, quality issues, and compliance.
• Creditors (BlackRock, HCR, CSL Vifor): Debt obligations and covenants under the BlackRock Credit Agreement and royalty agreements. Financial performance and ability to meet revenue projections directly impact repayment capabilities.

Next Steps

• Continue increasing prescribing access and depth for Vafseo among dialysis organizations.
• Generate additional data for Vafseo to educate physicians on potential clinical benefits and differentiation.
• Report top-line data from the VOICE trial in early 2027.
• Report top-line data from the VOCAL trial in late 2026.
• Continue engaging with the FDA regarding smaller subpopulations of CKD non-dialysis dependent patients for Vafseo.
• Continue to support the commercial availability of Auryxia.
• Continue enrolling patients in the Phase 2 clinical trial of praliciguat for FSGS.
• Initiate a Phase 2 basket study for AKB-097 in IgAN, C3G, and LN in the second half of 2026.
• Expect to report initial data from the AKB-097 study in 2027.
• Initiate a Phase 1 study of AKB-9090 in healthy volunteers in the first half of 2026.
• Explore potential use of AKB-9090 in ARDS.
• Continue preclinical development of AKB-10108 for ROP and other indications.
• Explore additional commercial and development opportunities to expand the pipeline.
• Relocate corporate headquarters to Waltham, Massachusetts in September 2026.
• Request a meeting with the FDA regarding enrollment and retention challenges in the Auryxia pediatric study.

Key Dates

Recommendation

Akebia Therapeutics shows promising revenue growth from Vafseo's U.S. launch and has a robust pipeline targeting unmet needs in rare kidney diseases. However, the immediate impact of Auryxia's loss of exclusivity and expected generic competition, coupled with the discontinuation of Vafseo's broad non-dialysis label expansion, introduces significant near-term headwinds and uncertainty. While the long-term pipeline holds potential, it is still in early to mid-stages of development. The company's financial position has improved, but it still carries a substantial accumulated deficit and faces ongoing R&D and commercialization costs. A 'hold' recommendation is appropriate as investors should monitor the successful navigation of generic competition for Auryxia, the continued uptake and adherence for Vafseo in its approved indication, and the progress of the rare kidney disease pipeline before making further investment decisions.

Keywords

Akebia Therapeutics, AKBA, Vafseo, Auryxia, vadadustat, ferric citrate, chronic kidney disease, CKD, anemia, dialysis, hyperphosphatemia, rare kidney disease, praliciguat, FSGS, AKB-097, IgA Nephropathy, C3 Glomerulopathy, Lupus Nephritis, AKB-9090, CS-AKI, biopharmaceutical, SEC filing, 10-K, financial results, pipeline, drug development, commercialization, intellectual property, regulatory approval, FDA, EMA, generic competition, capital raise